ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,970 | -51.1% | 11,367 | -6.2% | 0.00% | 0.0% |
| Q2 2023 | $259,411 | -44.3% | 12,122 | +5.2% | 0.00% | -50.0% |
| Q1 2023 | $465,788 | +76133.7% | 11,518 | -12.4% | 0.00% | -33.3% |
| Q4 2022 | $611 | -7.7% | 13,142 | +3.0% | 0.00% | 0.0% |
| Q3 2022 | $662 | -99.9% | 12,756 | +6.4% | 0.00% | 0.0% |
| Q2 2022 | $567,000 | -33.8% | 11,994 | -0.2% | 0.00% | 0.0% |
| Q1 2022 | $856,000 | +12.0% | 12,022 | +17.5% | 0.00% | 0.0% |
| Q4 2021 | $764,000 | +27.3% | 10,228 | -3.0% | 0.00% | +50.0% |
| Q3 2021 | $600,000 | +28.8% | 10,547 | -0.3% | 0.00% | 0.0% |
| Q2 2021 | $466,000 | -12.4% | 10,583 | -1.9% | 0.00% | 0.0% |
| Q1 2021 | $532,000 | +23.1% | 10,783 | +5.1% | 0.00% | 0.0% |
| Q4 2020 | $432,000 | -0.5% | 10,260 | +8.1% | 0.00% | 0.0% |
| Q3 2020 | $434,000 | -8.8% | 9,487 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $476,000 | -9.5% | 9,487 | -7.3% | 0.00% | -33.3% |
| Q1 2020 | $526,000 | -18.2% | 10,232 | -1.6% | 0.00% | 0.0% |
| Q4 2019 | $643,000 | -9.2% | 10,402 | -11.8% | 0.00% | 0.0% |
| Q3 2019 | $708,000 | -22.1% | 11,789 | +9.4% | 0.00% | -25.0% |
| Q2 2019 | $909,000 | -12.2% | 10,780 | -0.5% | 0.00% | -20.0% |
| Q1 2019 | $1,035,000 | +40.1% | 10,831 | +3.8% | 0.01% | +25.0% |
| Q4 2018 | $739,000 | -11.7% | 10,434 | +6.6% | 0.00% | 0.0% |
| Q3 2018 | $837,000 | -26.9% | 9,784 | -0.9% | 0.00% | -33.3% |
| Q2 2018 | $1,145,000 | +38.5% | 9,877 | -3.4% | 0.01% | +50.0% |
| Q1 2018 | $827,000 | +24.7% | 10,222 | -9.5% | 0.00% | +33.3% |
| Q4 2017 | $663,000 | +22.3% | 11,296 | -2.4% | 0.00% | 0.0% |
| Q3 2017 | $542,000 | +22.3% | 11,572 | -5.9% | 0.00% | +50.0% |
| Q2 2017 | $443,000 | +16.9% | 12,303 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $379,000 | +8.3% | 12,303 | +17.8% | 0.00% | 0.0% |
| Q4 2016 | $350,000 | +25.9% | 10,446 | 0.0% | 0.00% | +100.0% |
| Q3 2016 | $278,000 | +20.9% | 10,446 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $230,000 | -25.1% | 10,446 | 0.0% | 0.00% | -50.0% |
| Q1 2016 | $307,000 | -8.9% | 10,446 | +2.4% | 0.00% | 0.0% |
| Q4 2015 | $337,000 | – | 10,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |